Fantastic update which confirms everything is going to plan and growth is only just getting started.
Key takeouts for me below:
SSK Global Distribution Agreement with BioMerieux
This expanded distribution agreement commenced in 1H17 andwas a primary driver of ITL BioMedical’s record result in February
The market opportunity for SSK globally is now very significant and set to grow
ITL believes the bioMerieux agreement in conjunction with other distributors has the potential to double or triple sales of SSK over the next two to three years
ITL BioMedical Product Portfolio
Multiple new products in the development pipeline are expected to be commercialised over the next 12 months
Potential for ITL’s bioMerieux global distribution agreements to be expanded to include other products
ITL Healthcare
Additional tenders and contract opportunities are currently being pursued
Summary
2H17 has been effected by historical seasonality but is set to see good growth in underlying revenue and profit.
ITL expects to announce strong FY results.
Ann: ITL Investor Update, page-2
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)